Skip to content

Effect of baby care products

A clinical study to evaluate the safety and efficacy of the baby care products on a healthy pediatric population of the age group 01-36 months. - None

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037399
Enrollment
228
Registered
2021-10-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1. Dabur Baby Lotion: Subjects will be evaluated on baseline, day 12 and day 30 Intervention2: 2. Dabur Baby Cream: Subjects will be evaluated on baseline, day 12 and day 30 Interventio

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in the age group 1-12 months, 12-24 months and 24-36 months in nearly equal ratio. (Both genders inclusive) 2. Subjects in general good health as determined from a recent medical history 3. Subjectââ?¬•s mother/legal representative, preferably mother willing to give a voluntary written informed consent and agree to come for regular follow up 4. Subjects mother/legal representative, preferably mother willing to abide by and comply with the study protocol 5. Subjects mother/legal representative agreeing not to use any other product of the same nature and change any habit or other regular products during the study period

Exclusion criteria

Exclusion criteria: 1. A known history or present condition or any other concern that may require medical attention 2. Subjects deemed unfit to participate in the study based on the general health and hygiene 3. Babies whose parents and/or authorized legal guardian are not willing to sign the informed consent

Design outcomes

Primary

MeasureTime frame
1. Pediatrician�s assessment for health and quality of life 2. Dermatological evaluation for signs of skin irritation and/or discomforts, skin conditionTimepoint: Screening Visit, Baseline Visit, Visit 1 and Visit 2

Secondary

MeasureTime frame
To evaluate the product acceptance & toleranceTimepoint: Screening Visit, Baseline Visit, Visit 1 and Visit 2

Countries

India

Contacts

Public ContactRitambhara

Dabur India Limited

sasibhushan.vedula@dabur.com01203378405

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026